Steroid avoidance with early intensified dosing of enteric-coated mycophenolate sodium: A randomized multicentre trial in kidney transplant recipients

Nephrology Dialysis Transplantation

Volumn 27, Issue 9, 2012, Pages 3651-3659

  Thierry, Antoine ^a   Mourad, Georges ^b   Büchler, Matthias ^c   Kamar, Nassim ^d   Villemain, Florence ^e   Heng, Anne Elisabeth ^f   Le Meur, Yannick ^g   Choukroun, Gabriel ^h,i   Toupance, Olivier ^j   Legendre, Christophe ^k   Lepogamp, Patrick ^l   Kessler, Michele ^m   Merville, Pierre ⁿ   Moulin, Bruno ^o   Quéré, Stéphane ^p   Terpereau, Arara ^p   Chaouche Teyara, Kamel ^p   Touchard, Guy ^a  

^a POITIERS UNIVERSITY HOSPITAL   (France)

^b LAPEYRONIE HOSPITAL   (France)

^c CHU BRETONNEAU   (France)

^d CHU RANGUEIL   (France)

^e ANGERS UNIVERSITY HOSPITAL   (France)

^f SERVICE DE RHUMATOLOGIE   (France)

^g SERVICE DE RHUMATOLOGIE   (France)

^h AMIENS UNIVERSITY HOSPITAL   (France)

ⁱ UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

^j HÔPITAL MAISON BLANCHE   (France)

^k HÔPITAL NECKER ENFANTS MALADES   (France)

^l PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^m UNIVERSITY HOSPITAL OF NANCY   (France)

ⁿ HÔPITAL PELLEGRIN   (France)

^o HÔPITAL CIVIL   (France)

^p NOVARTIS PHARMA K K   (Japan)

more..

Author keywords

EC MPS; enteric coated mycophenolate sodium; MMF; mycophenolic acid; myfortic

Indexed keywords

CREATININE; CYCLOSPORIN A; ENTERIC COATED MYCOPHENOLIC ACID; INTERLEUKIN 2 RECEPTOR ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; PREDNISONE; STEROID; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ACUTE GRAFT REJECTION; ADULT; AGED; ANEMIA; ARTICLE; CONSTIPATION; CONTROLLED STUDY; CREATININE CLEARANCE; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT RECIPIENT; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; URINARY TRACT INFECTION;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; CYCLOSPORINE; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PROGNOSIS; RENAL INSUFFICIENCY, CHRONIC; TABLETS, ENTERIC-COATED; WITHHOLDING TREATMENT; YOUNG ADULT;

EID: 84865735575     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs146     Document Type: Article

References (41)

1. Tarantino A, Montagnino G, Ponticelli C. Corticosteroids in kidney transplant recipients. Safety issues and timing of discontinuation. Drug Saf 1995; 13: 145-156.
2. Boots JM, Christiaans MH, van Hooff JP. Effect of immunosuppressive agents on long-term survival of renal transplant recipients: focus on the cardiovascular risk. Drugs 2004; 64: 2047-2073.
3. Veenstra DL, Best JH, Hornberger J et al. The incidence and longterm cost of steroid-related side effects after renal transplantation. Am J Kidney Dis 1999; 33: 829-839.
4. Hricik DE. Steroid-free immunosuppression in kidney transplantation: an editorial review. Am J Transplant 2002; 2: 19-24.
5. Pascual J, Zamora J, Galeano C et al. Steroid avoidance or withdrawal for kidney transplant recipients. Cochrane Database Syst Rev 2009; (1):CD005632.
6. Rike AH, Mogilishetty G, Alloway RR et al. Cardiovascular risk, cardiovascular events, and metabolic syndrome in renal transplantation: comparison of early steroid withdrawal and chronic steroids. Clin Transplant 2008; 22: 229-235.
7. Augustine JJ, Hricik DE. Steroid sparing in kidney transplantation: changing paradigms, improving outcomes, and remaining questions. Clin J Am Soc Nephrol 2006; 1: 1080-1089.
8. Gallon L, Perico N, Dimitrov BD et al. Long-term renal allograft function on a tacrolimus-based, pred-free maintenance immunosuppression comparing sirolimus vs. MMF. Am J Transplant 2006; 6: 1617-1623.
9. Montagnino G, Sandrini S, Iorio B et al. A randomized exploratory trial of steroid avoidance in renal transplant patients treated with everolimus and low-dose cyclosporine. Nephrol Dial Transplant 2008; 23: 707-714.
10. Woodle ES, Vincenti F, Lorber MI et al. A multicenter pilot study of early (4-day) steroid cessation in renal transplant recipients under simulect, tacrolimus and sirolimus. Am J Transplant 2005; 5: 157-166.
11. Kandaswamy R, Melancon JK, Dunn T et al. A prospective randomized trial of steroid-free maintenance regimens in kidney transplant recipients-an interim analysis. Am J Transplant 2005; 5: 1529-1536.
12. Vincenti F, Schena FP, Paraskevas S et al. A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant 2008; 8: 307-316.
13. Vincenti F, Monaco A, Grinyo J et al. Multicenter randomized prospective trial of steroid withdrawal in renal transplant recipients receiving basiliximab, cyclosporine microemulsion and mycophenolate mofetil. Am J Transplant 2003; 3: 306-311.
14. Rostaing L, Cantarovich D, Mourad G et al. Corticosteroid free immunosuppression with tacrolimus, mycophenolate mofetil and daclizumab induction in renal transplantation. Transplantation 2005; 79: 807-814.
15. Kumar MS, Xiao SG, Fyfe B et al. Steroid avoidance in renal transplantation using basiliximab induction, cyclosporine-based immunosuppression and protocol biopsies. Clin Transplant 2005; 19: 61-69.
16. Sommerer C, Glander P, Arns Wet al. Safety and efficacy of intensified versus standard dosing regimens of enteric-coated mycophenolate sodium in de novo renal transplant patients. Transplantation 2011; 91: 779-785.
17. Glander P, Sommerer C, Arns Wet al. Pharmacokinetics and pharmacodynamics of intensified versus standard dosing of mycophenolate sodium in renal transplant patients. Clin J Am Soc Nephrol 2010; 5: 503-511.
18. Gourishankar S, Houde I, Keown PA et al. The CLEAR study: a 5-day, 3-g loading dose of mycophenolate mofetil versus standard 2-g dosing in renal transplantation. Clin J Am Soc Nephrol 2010; 5: 1282-1289.
19. Racusen L, Solez K, Colvin R et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713-723.
20. Racusen LC, Halloran PF, Solez K. Banff 2003 meeting report: new diagnostic insights and standards. Am J Transplant 2004; 4: 1562-1566.
21. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
22. Nankivell BJ, Gruenewald SM, Allen RD et al. Predicting glomerular filtration rate after kidney transplantation. Transplantation 1995; 59: 1683-1689.
23. Kamar N, Garrigue V, Karras A et al. Impact of early or delayed cyclosporine on delayed graft function in renal transplant recipients: a randomized, multicenter study. Am J Transplant 2006; 6: 1042-1048.
24. Le Meur Y, Büchler M, Thierry A et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant 2007; 7: 2496-2503.
25. Salvadori M, Holzer H, de Mattos A et al. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2004; 4: 231-236.
26. de Winter BC, van Gelder T, Glander P et al. Population pharmacokinetics of mycophenolic acid: a comparison between enteric-coated mycophenolate sodium and mycophenolate mofetil in renal transplant recipients. Clin Pharmacokinet 2008; 47: 827-838.
27. Legendre C, Cohen D, Zeier M et al. Efficacy and safety of entericcoated mycophenolate sodium in de novo renal transplant recipients: pooled data from three 1-month multicenter, open-label prospective studies. Transplant Proc 2007; 39: 1386-1391.
28. Knight SR, Morris PJ. Steroid avoidance or withdrawal after renal transplantation increases the risk of acute rejection but decreases cardiovascular risk. A meta-analysis. Transplantation 2010; 89: 1-14.
29. Kahwaji J, Bunnapradist S, Hus JW et al. Cause of death with graft function among renal transplant recipients in an integrated healthcare system. Transplantation 2011; 91: 225-230.
30. Linares L, Cofán F, Cervera C et al. Infection-related mortality in a large cohort of renal transplant recipients. Transplant Proc 2007; 39: 2225-2227.
31. Egli A, Binggeli S, Bodaghi S et al. Cytomegalovirus and polyomavirus BK posttransplant. Nephrol Dial Transplant 2007; 22 (Suppl 8): viii72-viii82.
32. Cole EH, Johnston O, Rose CL et al. Impact of acute rejection and new-onset diabetes on long-term transplant graft and patient survival. Clin J Am Soc Nephrol 2008; 3: 814-821.
33. Hjelmesaeth J, Hartmann A, Leivestad H et al. The impact of earlydiagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events. Kidney Int 2006; 69: 588-595.
34. Webster AC, Woodroffe RC, Taylor RS et al. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ 2005; 331: 810-820.
35. Hirsch HH, Brennan DC, Drachenberg CB et al. Polyomavirusassociated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation 2005; 79: 1277-1286.
36. Brennan DC, Agha I, Bohl DL et al. Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. Am J Transplant 2005; 5: 582-594.
37. Hirsch HH, Vincenti F, Friman S et al. Prospective study of polyomavirus BK viruria and viremia in de novo renal transplantation comparing cyclosporine and tacrolimus: a multivariate analysis. Am J Transplant 2009; 9 (Suppl 3): 337; Abstract 505.
38. de Winter BC, Mathot RA, Sombogaard F et al. Nonlinear relationship between mycophenolate mofetil dose and mycophenolic acid exposure: implications for therapeutic drug monitoring. Clin J Am Soc Nephrol 2011; 6: 656-663.
39. Ciancio G, Burke GW, Gaynor JJ et al. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up. Transplantation 2008; 86: 67-74.
40. Ratcliffe PJ, Dudley CR, Higgins RM et al. Randomised controlled trial of steroid withdrawal in renal transplant recipients receiving triple immunosuppression. Lancet 1996; 348: 643-648.
41. Vanrenterghem Y, Lebranchu Y, Hené R et al. Double-blind comparison of two corticosteroid regimens plus mycophenolate mofetil and cyclosporine for prevention of acute renal allograft rejection. Transplantation 2000; 70: 1352-1359.